Year All2024202320222021202020192018 April 11, 2024 Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market April 10, 2024 Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development April 8, 2024 Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting April 4, 2024 Oculis to Participate at Upcoming April Investor Conferences March 18, 2024 Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress February 28, 2024 Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments January 29, 2024 Oculis to Present at Upcoming February Investor Conferences January 22, 2024 Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
April 11, 2024 Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
April 10, 2024 Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
April 8, 2024 Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
February 28, 2024 Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments